|
1
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar
|
|
2
|
Pan R, Zhu M, Yu C, Lv J, Guo Y, Bian Z,
Yang L, Chen Y, Hu Z, Chen Z, et al China Kadoorie Biobank
Collaborative Group: Cancer incidence and mortality: A cohort study
in China, 2008-2013. Int J Cancer. 141:1315–1323. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Zhang S, Zeng H, Xia C,
Zuo T, Yang Z, Zou X and He J: Cancer incidence and mortality in
China, 2013. Cancer Lett. 401:63–71. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shin A, Jung KW and Won YJ: Colorectal
cancer mortality in Hong Kong of China, Japan, South Korea, and
Singapore. World J Gastroenterol. 19:979–983. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fitzgerald TL, Biswas T, O'Brien K, Zervos
EE and Wong JH: Neoadjuvant radiotherapy for rectal cancer:
Adherence to evidence-based guidelines in clinical practice. World
J Surg. 37:639–645. 2013. View Article : Google Scholar
|
|
6
|
Murray DM, Katz ML, Post DM, Pennell ML,
Young GS, Tatum CM and Paskett ED: Enhancing cancer screening in
primary care: Rationale, design, analysis plan, and recruitment
results. Contemp Clin Trials. 34:356–363. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Halabi WJ, Kang CY, Jafari MD, Nguyen VQ,
Carmichael JC, Mills S, Stamos MJ and Pigazzi A: Robotic-assisted
colorectal surgery in the United States: A nationwide analysis of
trends and outcomes. World J Surg. 37:2782–2790. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu YW and Wang KH: Research progress on
genetic heterogeneity between primary and paired metastatic
colorectal cancer. Yi Chuan. 39:482–490. 2017.PubMed/NCBI
|
|
9
|
Kopetz S, Chang GJ, Overman MJ, Eng C,
Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM and
McWilliams RR: Improved survival in metastatic colorectal cancer is
associated with adoption of hepatic resection and improved
chemotherapy. J Clin Oncol. 27:3677–3683. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Loree JM and Kopetz S: Recent developments
in the treatment of metastatic colorectal cancer. Ther Adv Med
Oncol. 9:551–564. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Midgley RS, Yanagisawa Y and Kerr DJ:
Evolution of nonsurgical therapy for colorectal cancer. Nat Clin
Pract Gastroenterol Hepatol. 6:108–120. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McCubrey JA, Lertpiriyapong K, Steelman
LS, Abrams SL, Yang LV, Murata RM, Rosalen PL, Scalisi A, Neri LM,
Cocco L, et al: Effects of resveratrol, curcumin, berberine and
other nutra-ceuticals on aging, cancer development, cancer stem
cells and microRNAs. Aging (Albany NY). 9:1477–1536. 2017.
|
|
13
|
de Lima E Silva TC, da Silveira LTR,
Fragoso MF, da Silva FRM, Martinez MF, Zapaterini JR, Diniz OHG,
Scarano WR and Barbisan LF: Maternal resveratrol treatment reduces
the risk of mammary carcinogenesis in female offspring prenatally
exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Horm Cancer.
8:286–297. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Perez-Vizcaino F and Fraga CG: Research
trends in flavonoids and health. Arch Biochem Biophys. 646:107–112.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Darwish MA, Abo-Youssef AM, Khalaf MM,
Abo-Saif AA, Saleh IG and Abdelghany TM: Resveratrol influences
platinum pharmacokinetics: A novel mechanism in protection against
cisplatin-induced nephrotoxicity. Toxicol Lett. 290:73–82. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kiskova T, Demeckova V, Jendzelovska Z,
Kiktava M, Venglovska K, Bohmdorfer M, Jager W and Thalhammer T:
Nocturnal resveratrol administration inhibits chemically induced
breast cancer formation in rats. J Physiol Pharmacol. 68:867–875.
2017.
|
|
17
|
Guthrie AR, Chow HS and Martinez JA:
Effects of resveratrol on drug- and carcinogen-metabolizing
enzymes, implications for cancer prevention. Pharmacol Res
Perspect. 5:e002942017. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bartolacci C, Andreani C, Amici A and
Marchini C: Walking a tightrope: A perspective of resveratrol
effects on breast cancer. Curr Protein Pept Sci. 19:311–322. 2018.
View Article : Google Scholar
|
|
19
|
Rauf A, Imran M, Butt MS, Nadeem M, Peters
DG and Mubarak MS: Resveratrol as an anti-cancer agent: A review.
Crit Rev Food Sci Nutr. 58:1428–1447. 2018. View Article : Google Scholar
|
|
20
|
Feng Y, Zhou J and Jiang Y: Resveratrol in
lung cancer- a systematic review. J BUON. 21:950–953.
2016.PubMed/NCBI
|
|
21
|
Yin TF, Wang M, Qing Y, Lin YM and Wu D:
Research progress on chemopreventive effects of phytochemicals on
colorectal cancer and their mechanisms. World J Gastroenterol.
22:7058–7068. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li C, Xu X, Tao Z, Sun C and Pan Y:
Resveratrol derivatives: An updated patent review (2012–2015).
Expert Opin Ther Pat. 1–12. 2016.
|
|
23
|
Li YH, Niu YB, Sun Y, Zhang F, Liu CX, Fan
L and Mei QB: Role of phytochemicals in colorectal cancer
prevention. World J Gastroenterol. 21:9262–9272. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fajardo AM and Piazza GA: Chemoprevention
in gastrointestinal physiology and disease. Anti-inflammatory
approaches for colorectal cancer chemoprevention. Am J Physiol
Gastrointest Liver Physiol. 309:G59–G70. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Carter LG, D'Orazio JA and Pearson KJ:
Resveratrol and cancer: Focus on in vivo evidence. Endocr Relat
Cancer. 21:R209–R225. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Juan ME, Alfaras I and Planas JM:
Colorectal cancer chemoprevention by trans-resveratrol. Pharmacol
Res. 65:584–591. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gong WH, Zhao N, Zhang ZM, Zhang YX, Yan L
and Li JB: The inhibitory effect of resveratrol on COX-2 expression
in human colorectal cancer: A promising therapeutic strategy. Eur
Rev Med Pharmacol Sci. 21:1136–1143. 2017.PubMed/NCBI
|
|
28
|
Karimi Dermani F, Saidijam M, Amini R,
Mahdavinezhad A, Heydari K and Najafi R: Resveratrol inhibits
proliferation, invasion, and epithelial-mesenchymal transition by
increasing miR-200c expression in HCT-116 colorectal cancer cells.
J Cell Biochem. 118:1547–1555. 2017. View Article : Google Scholar
|
|
29
|
Buhrmann C, Shayan P, Popper B, Goel A and
Shakibaei M: Sirt1 is required for resveratrol-mediated
chemopreventive effects in colorectal cancer cells. Nutrients.
8:1452016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Baou M, Jewell A and Murphy JJ: TIS11
family proteins and their roles in posttranscriptional gene
regulation. J Biomed Biotechnol. 2009:6345202009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li C, Tang C and He G: Tristetraprolin: A
novel mediator of the anticancer properties of resveratrol. Genet
Mol Res. 15:152016.
|
|
32
|
Deng K, Wang H, Shan T, Chen Y, Zhou H,
Zhao Q and Xia J: Tristetraprolin inhibits gastric cancer
progression through suppression of IL-33. Sci Rep. 6:245052016.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pandiri I, Chen Y, Joe Y, Kim HJ, Park J,
Chung HT and Park JW: Tristetraprolin mediates the
anti-proliferative effects of metformin in breast cancer cells.
Breast Cancer Res Treat. 156:57–64. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wei ZR, Liang C, Feng D, Cheng YJ, Wang
WM, Yang DJ, Wang YX and Cai QP: Low tristetraprolin expression
promotes cell proliferation and predicts poor patients outcome in
pancreatic cancer. Oncotarget. 7:17737–17750. 2016.PubMed/NCBI
|
|
35
|
Xu L, Ning H, Gu L, Wang Q, Lu W, Peng H,
Cui W, Ying B, Ross CR, Wilson GM, et al: Tristetraprolin induces
cell cycle arrest in breast tumor cells through targeting
AP-1/c-Jun and NF-κB pathway. Oncotarget. 6:41679–41691. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sobolewski C, Sanduja S, Blanco FF, Hu L
and Dixon DA: Histone deacetylase inhibitors activate
tristetraprolin expression through induction of early growth
response protein 1 (EGR1) in colorectal cancer cells. Biomolecules.
5:2035–2055. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kang S, Min A, Im SA, Song SH, Kim SG, Kim
HA, Kim HJ, Oh DY, Jong HS, Kim TY, et al: TGF-β suppresses COX-2
expression by tristetraprolin-mediated RNA destabilization in A549
human lung cancer cells. Cancer Res Treat. 47:101–109. 2015.
View Article : Google Scholar
|
|
38
|
Lee HH, Son YJ, Lee WH, Park YW, Chae SW,
Cho WJ, Kim YM, Choi HJ, Choi DH, Jung SW, et al: Tristetraprolin
regulates expression of VEGF and tumorigenesis in human colon
cancer. Int J Cancer. 126:1817–1827. 2010. View Article : Google Scholar
|
|
39
|
Ryu J, Yoon NA, Seong H, Jeong JY, Kang S,
Park N, Choi J, Lee DH, Roh GS, Kim HJ, et al: Resveratrol induces
glioma cell apoptosis through activation of tristetraprolin. Mol
Cells. 38:991–997. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lee JY, Kim HJ, Yoon NA, Lee WH, Min YJ,
Ko BK, Lee BJ, Lee A, Cha HJ, Cho WJ, et al: Tumor suppressor p53
plays a key role in induction of both tristetraprolin and let-7 in
human cancer cells. Nucleic Acids Res. 41:5614–5625. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim CW, Kim HK, Vo MT, Lee HH, Kim HJ, Min
YJ, Cho WJ and Park JW: Tristetraprolin controls the stability of
cIAP2 mRNA through binding to the 3′UTR of cIAP2 mRNA. Biochem
Biophys Res Commun. 400:46–52. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lee HH, Lee SR and Leem SH:
Tristetraprolin regulates prostate cancer cell growth through
suppression of E2F1. J Microbiol Biotechnol. 24:287–294. 2014.
View Article : Google Scholar
|
|
43
|
Lee HH, Vo MT, Kim HJ, Lee UH, Kim CW, Kim
HK, Ko MS, Lee WH, Cha SJ, Min YJ, et al: Stability of the LATS2
tumor suppressor gene is regulated by tristetraprolin. J Biol Chem.
285:17329–17337. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kim CW, Vo MT, Kim HK, Lee HH, Yoon NA,
Lee BJ, Min YJ, Joo WD, Cha HJ, Park JW, et al: Ectopic
over-expression of tristet-raprolin in human cancer cells promotes
biogenesis of let-7 by down-regulation of Lin28. Nucleic Acids Res.
40:3856–3869. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li W, Matsuoka M, Kai M, Thapa P, Khadge
S, Hagge DA, Brennan PJ and Vissa V: Real-time PCR and
high-resolution melt analysis for rapid detection of Mycobacterium
leprae drug resistance mutations and strain types. J Clin
Microbiol. 50:742–753. 2012. View Article : Google Scholar :
|
|
46
|
Ashrafi R, Bruneaux M, Sundberg LR,
Pulkkinen K and Ketola T: Application of high resolution melting
assay (HRM) to study temperature-dependent intraspecific
competition in a pathogenic bacterium. Sci Rep. 7:9802017.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Du Z, Zhou F, Jia Z, Zheng B, Han S, Cheng
J, Zhu G and Huang P: The hedgehog/Gli-1 signaling pathways is
involved in the inhibitory effect of resveratrol on human
colorectal cancer HCT116 cells. Iran J Basic Med Sci. 19:1171–1176.
2016.PubMed/NCBI
|
|
48
|
Feng M, Zhong LX, Zhan ZY, Huang ZH and
Xiong JP: Resveratrol treatment inhibits proliferation of and
induces apoptosis in human colon cancer cells. Med Sci Monit.
22:1101–1108. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ali I and Braun DP: Resveratrol enhances
mitomycin C-mediated suppression of human colorectal cancer cell
proliferation by up- regulation of p21WAF1/CIP1. Anticancer Res.
34:5439–5446. 2014.PubMed/NCBI
|
|
50
|
Liu B, Zhou Z, Zhou W, Liu J, Zhang Q, Xia
J, Liu J, Chen N, Li M and Zhu R: Resveratrol inhibits
proliferation in human colorectal carcinoma cells by inducing
G1/S-phase cell cycle arrest and apoptosis through
caspase/cyclin-CDK pathways. Mol Med Rep. 10:1697–1702. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Guo J, Qu H, Chen Y and Xia J: The role of
RNA-binding protein tristetraprolin in cancer and immunity. Med
Oncol. 34:1962017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Guo J, Wang H, Jiang S, Xia J and Jin S:
The Cross-talk between tristetraprolin and cytokines in cancer.
Anticancer Agents Med Chem. 17:1477–1486. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang Q, Ning H, Peng H, Wei L, Hou R, Hoft
DF and Liu J: Tristetraprolin inhibits macrophage IL-27-induced
activation of antitumour cytotoxic T cell responses. Nat Commun.
8:8672017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Vo MT, Choi SH, Lee JH, Hong CH, Kim JS,
Lee UH, Chung HM, Lee BJ, Park JW and Cho WJ: Tristetraprolin
inhibits mitochondrial function through suppression of α-Synuclein
expression in cancer cells. Oncotarget. 8:41903–41920. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zeng B, Zhu D, Su Z, Li Z and Yu Z:
Tristetraprolin exerts tumor suppressive functions on the
tumorigenesis of glioma by targeting IL-13. Int Immunopharmacol.
39:63–70. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lee HH, Yang SS, Vo MT, Cho WJ, Lee BJ,
Leem SH, Lee SH, Cha HJ and Park JW: Tristetraprolin down-regulates
IL-23 expression in colon cancer cells. Mol Cells. 36:571–576.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Cha HJ, Lee HH, Chae SW, Cho WJ, Kim YM,
Choi HJ, Choi DH, Jung SW, Min YJ, Lee BJ, et al: Tristetraprolin
downregulates the expression of both VEGF and COX-2 in human colon
cancer. Hepatogastroenterology. 58:790–795. 2011.PubMed/NCBI
|
